课题基金 / 基金详情

Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Novel Therapeutics for Schizophrenia: Determining the Mechanisms of Action Underlying Cognition-enhancing and Antipsychotic-like Effects

Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Novel Therapeutics for Schizophrenia: Determining the Mechanisms of Action Underlying Cognition-enhancing and Antipsychotic-like Effects
代谢型谷氨酸受体 5 的正变构调节剂作为精神分裂症的新疗法：确定认知增强和抗精神病样作用的作用机制
批准号：
347886
负责人：
Maksymetz James
金额：
$7.65万
依托单位：
Vanderbilt University (Tennessee)
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2015
资助国家：
加拿大
项目状态：
已结题
起止时间：
2015-10-01 至 2018-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=347886&lang=en
关键词：
Antipsychotics Brain Function Cognition Drug Development Electrophysiology Metabotropic Glutamate Receptors Positive Allosteric Modulators Schizophrenia Signal Bias Synaptic Plasticity

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Schizophrenia is a debilitating, mental illness that affects 1% of Canadians and is associated with positive (e.g. hallucinations), negative (e.g. flattened affect), and cognitive (e.g. impaired working memory) symptoms. Current drugs are effective at ame
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金